Perrigo Company plc Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Perrigo Company plc (PRGO) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $18.10 million for the 3-month period ending 2019-09-28, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2021-03-01
- Perrigo Company plc impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2019-09-28 was $18.10M.
- Perrigo Company plc impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2018-06-30 was $53.20M.
- Perrigo Company plc impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2017-04-01 was $12.20M, a 95.54% decline year-over-year.
- Perrigo Company plc impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2016-04-02 was $273.40M.
- Perrigo Company plc impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2017 was $12.70M, a 98.51% decline from fiscal 2016.
- Perrigo Company plc impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2016 was $849.50M.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|
| 2019-09-28 | $18.10M 10-K · filed 2021-03-01 | ||
| 2018-06-30 | $53.20M 10-K · filed 2020-02-27 | ||
| 2017-12-31 | $12.70M 10-K · filed 2018-03-01 | ||
| 2017-04-01 | $12.20M 10-K · filed 2019-02-27 | ||
| 2016-12-31 | $849.50M 10-K · filed 2018-03-01 | ||
| 2016-10-03 | $849.10M 10-K · filed 2017-05-22 | ||
| 2016-04-02 | $273.40M 10-Q/A · filed 2017-05-22 | ||
| 2015-12-31 | $185.10M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |